CA2561645A1 - A method of treatment for stroke employing administration of defibrinogenating agents to achieve a specific defibrinogenation pattern - Google Patents
A method of treatment for stroke employing administration of defibrinogenating agents to achieve a specific defibrinogenation pattern Download PDFInfo
- Publication number
- CA2561645A1 CA2561645A1 CA002561645A CA2561645A CA2561645A1 CA 2561645 A1 CA2561645 A1 CA 2561645A1 CA 002561645 A CA002561645 A CA 002561645A CA 2561645 A CA2561645 A CA 2561645A CA 2561645 A1 CA2561645 A1 CA 2561645A1
- Authority
- CA
- Canada
- Prior art keywords
- ancrod
- treatment
- defibrinogenation
- fibrinogen
- stroke
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000003536 defibrinogenating effect Effects 0.000 title claims abstract description 79
- 238000000034 method Methods 0.000 title claims abstract description 34
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 68
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 68
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 68
- 108010001779 Ancrod Proteins 0.000 claims description 92
- 229960004233 ancrod Drugs 0.000 claims description 88
- 238000010606 normalization Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 4
- 206010018985 Haemorrhage intracranial Diseases 0.000 abstract description 22
- 208000008574 Intracranial Hemorrhages Diseases 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 20
- 208000032382 Ischaemic stroke Diseases 0.000 abstract description 14
- 230000002035 prolonged effect Effects 0.000 abstract description 7
- 230000002411 adverse Effects 0.000 abstract description 4
- 208000006011 Stroke Diseases 0.000 description 35
- 239000000902 placebo Substances 0.000 description 34
- 229940068196 placebo Drugs 0.000 description 34
- 238000001802 infusion Methods 0.000 description 28
- 239000003795 chemical substances by application Substances 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 11
- 206010051125 Hypofibrinogenaemia Diseases 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 108090000190 Thrombin Proteins 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 229960004072 thrombin Drugs 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 6
- 210000001772 blood platelet Anatomy 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 229950003499 fibrin Drugs 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 108010073385 Fibrin Proteins 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 101800000974 Fibrinopeptide A Proteins 0.000 description 3
- 101800003778 Fibrinopeptide B Proteins 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 102000013566 Plasminogen Human genes 0.000 description 3
- 108010051456 Plasminogen Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 241000271064 Calloselasma rhodostoma Species 0.000 description 2
- 108010071289 Factor XIII Proteins 0.000 description 2
- 108010088842 Fibrinolysin Proteins 0.000 description 2
- 102400001063 Fibrinopeptide B Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 201000008247 brain infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 229940012444 factor xiii Drugs 0.000 description 2
- 230000003480 fibrinolytic effect Effects 0.000 description 2
- MYRIFIVQGRMHRF-OECXYHNASA-N fibrinopeptide b Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)CNC(=O)[C@@H]1CCC(=O)N1 MYRIFIVQGRMHRF-OECXYHNASA-N 0.000 description 2
- 230000005021 gait Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000007971 neurological deficit Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- JWICNZAGYSIBAR-LEEGLKINSA-N (4s)-4-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-5-[[2-[[(2s)-3-carboxy-1-[[(2s)-1-[[1-[[(2s)-1-[[(2s)-4-carboxy-1-[[2-[[2-[[2-[[(2s)-1-[[(1s)-1-carboxy-4-(diaminomethylideneamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)C(CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)N)CC1=CC=CC=C1 JWICNZAGYSIBAR-LEEGLKINSA-N 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000271581 Calloselasma Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- FBPFZTCFMRRESA-ZXXMMSQZSA-N D-iditol Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-ZXXMMSQZSA-N 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 102400000525 Fibrinopeptide A Human genes 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000000179 crotalid venom Substances 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000033885 plasminogen activation Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003354 serine derivatives Chemical class 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/812,510 US20050220782A1 (en) | 2004-03-30 | 2004-03-30 | Method of treatment for stroke employing administration of defibrinogenating agents to achieve a specific defibrinogenation pattern |
| US10/812,510 | 2004-03-30 | ||
| PCT/US2005/010769 WO2005097262A1 (en) | 2004-03-30 | 2005-03-30 | A method of treatment for stroke employing administration of defibrinogenating agents to achieve a specific defibrinogenation pattern |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2561645A1 true CA2561645A1 (en) | 2005-10-20 |
Family
ID=34964955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002561645A Abandoned CA2561645A1 (en) | 2004-03-30 | 2005-03-30 | A method of treatment for stroke employing administration of defibrinogenating agents to achieve a specific defibrinogenation pattern |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20050220782A1 (https=) |
| EP (1) | EP1740271A1 (https=) |
| JP (1) | JP2007531759A (https=) |
| AU (1) | AU2005231769A1 (https=) |
| CA (1) | CA2561645A1 (https=) |
| IL (1) | IL178426A0 (https=) |
| RU (1) | RU2006138043A (https=) |
| WO (1) | WO2005097262A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102016110642A1 (de) * | 2016-06-09 | 2017-12-14 | Nordmark Holding Gmbh | Verwendung von Ancrod zur Vorbeugung und/oder Behandlung von Ischämie |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5523292A (en) * | 1992-10-14 | 1996-06-04 | Schwartz; Robert | Method of preventing restenosis following coronary angioplasty |
| US6165795A (en) * | 1998-06-25 | 2000-12-26 | Cardiovascular Diagnostics, Inc. | Methods for performing fibrinogen assays using dry chemical reagents containing ecarin and magnetic particles |
-
2004
- 2004-03-30 US US10/812,510 patent/US20050220782A1/en not_active Abandoned
-
2005
- 2005-03-30 EP EP05733220A patent/EP1740271A1/en not_active Withdrawn
- 2005-03-30 JP JP2007506521A patent/JP2007531759A/ja not_active Withdrawn
- 2005-03-30 WO PCT/US2005/010769 patent/WO2005097262A1/en not_active Ceased
- 2005-03-30 RU RU2006138043/14A patent/RU2006138043A/ru not_active Application Discontinuation
- 2005-03-30 CA CA002561645A patent/CA2561645A1/en not_active Abandoned
- 2005-03-30 AU AU2005231769A patent/AU2005231769A1/en not_active Abandoned
-
2006
- 2006-10-03 IL IL178426A patent/IL178426A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005231769A1 (en) | 2005-10-20 |
| IL178426A0 (en) | 2007-02-11 |
| RU2006138043A (ru) | 2008-05-10 |
| JP2007531759A (ja) | 2007-11-08 |
| US20050220782A1 (en) | 2005-10-06 |
| WO2005097262A1 (en) | 2005-10-20 |
| EP1740271A1 (en) | 2007-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5180583A (en) | Method for the treatment of bleeding disorders | |
| DE3855096T2 (de) | Hemmung von arteriellem thrombotischen Verschluss oder von Thrombo-Embolismus | |
| JP3805981B2 (ja) | 凝固亢進状態または後天性プロテインｃ欠乏症を処置する方法 | |
| CA1281647C (en) | Compositions and methods for the treatment of bleeding disorders | |
| CN1090029C (zh) | 溶血栓活性蛋白和抗凝血剂的组合物及其应用 | |
| Mombelli et al. | Effect of heparin on plasma fibrinopeptide A in patients with acute myocardial infarction. | |
| US5009889A (en) | Treatment of dysfunctional vascular endothelium using activated protein C | |
| Agnelli et al. | Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin | |
| Woessner et al. | Influence of a long-term, high-dose volume therapy with 6% hydroxyethyl starch 130/0.4 or crystalloid solution on hemodynamics, rheology and hemostasis in patients with acute ischemic stroke: Results of a randomized, placebo-controlled, double-blind study | |
| Siegbahn et al. | Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo | |
| Mariani et al. | Treatment of congenital factor VII deficiency with a new concentrate | |
| US5690931A (en) | Method for treating thromboembolic conditions via the use of multiple bolus administration of thrombolytically active proteins | |
| Rapold et al. | Requirement of heparin for arterial and venous thrombolysis with recombinant tissue-type plasminogen activator | |
| CA2561645A1 (en) | A method of treatment for stroke employing administration of defibrinogenating agents to achieve a specific defibrinogenation pattern | |
| Köhler et al. | High-dose systemic streptokinase and acylated streptokinase-plasminogen complex (BRL 26921) in acute myocardial infarction: alterations of the fibrinolytic system and clearance of fibrinolytic activity | |
| EP1133314B1 (en) | Protein c for the treatment of sickle cell disease and thalassemia | |
| US5342616A (en) | Method of administering tissue plasminogen activator | |
| Huet et al. | Low Molecular Weight Heparin Fraction PK10169: A New Therapeutic Means for Anticoagulant Therapy? | |
| Mola et al. | A pilot study of pro-urokinase in the treatment of deep vein thrombosis | |
| JP2783367B2 (ja) | ヘパリン含有製剤 | |
| Huet et al. | Treatment of acute pulmonary embolism by a low molecular weight heparin fraction. A preliminary study | |
| Liu‐DeRyke et al. | Hemostatic therapy for the treatment of intracranial hemorrhage | |
| EP0352897B1 (en) | Tpa-containing medicaments | |
| EP0733371B1 (de) | Mittel zur subkutanen Verabreichung von Protein C | |
| Bizzi et al. | Pretreatment with Heparin in Thrombolytic Therapy with Urokinase: Heparin-Urokinase Therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |